Sk Biopharmaceuticals Co Ltd (326030.KS) Diversifiers
Equity · Currency in KRW · Last updated Jun 5, 2026
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company has collaborative research agreement with Korea Institute of Radiological and Medical Sciences for discovering and developing radiopharmaceutical drug candidates using an alpha-particle emitting radioisotope, actinium-225, for potential cancer treatments; and research collaboration agreement with ProEn Therapeutics for accelerating expansion of oncology research and pipeline for radiopharmaceuticals. SK Biopharmaceuticals Co., Ltd. was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc
Looking to balance out your exposure to 326030.KS? The ETFs below have the lowest correlation with 326030.KS — they tend to move on their own, which can help reduce risk when 326030.KS drops. The stock ideas table highlights individual companies that behave independently from 326030.KS.
No Diversifiers Found for 326030.KS
We do not have enough correlation history to rank diversifiers for this symbol yet.
Diversification Analysis
Build a portfolio that complements 326030.KS
Add 326030.KS to the Diversification Analyzer to see how it overlaps with your other holdings and which assets balance it best.
